CytoMed Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 42

Employees

  • Stock Symbol
  • GDTC

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.77
  • (As of Monday Closing)

CytoMed Therapeutics General Information

Description

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1 Commonwealth Lane
  • No. 08-22 One Commonwealth
  • Singapore, 149544
  • Singapore
+65 6250
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Delivery
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1 Commonwealth Lane
  • No. 08-22 One Commonwealth
  • Singapore, 149544
  • Singapore
+65 6250

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoMed Therapeutics Stock Performance

As of 16-Nov-2026, CytoMed Therapeutics’s stock price is $0.77. Its current market cap is $9.2M with 11.9M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.77 $0.83 $0.68 - $2.29 $9.2M 11.9M 17.1K -$0.23

CytoMed Therapeutics Financials Summary

As of 30-Jun-2026, CytoMed Therapeutics has a trailing 12-month revenue of $254K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 11,173 13,870 34,782 49,145
Revenue 254 248 52 0
EBITDA (2,424) (2,829) (1,859) (2,967)
Net Income (2,731) (3,045) (1,883) (3,077)
Total Assets 5,425 6,214 7,405 9,365
Total Debt 892 376 341 339
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CytoMed Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CytoMed Therapeutics‘s full profile, request access.

Request a free trial

CytoMed Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore CytoMed Therapeutics‘s full profile, request access.

Request a free trial

CytoMed Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies
Other Pharmaceuticals and Biotechnology
Singapore, Singapore
42 As of 2026

San Diego, CA
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CytoMed Therapeutics Competitors (6)

One of CytoMed Therapeutics’s 6 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fate Therapeutics Formerly VC-backed San Diego, CA
Century Therapeutics Formerly VC-backed Philadelphia, PA
Autolus Formerly VC-backed London, United Kingdom
Bristol-Myers Squibb Corporation Princeton, NJ
Gilead Formerly VC-backed Foster City, CA
To view CytoMed Therapeutics’s complete competitors history, request access »

CytoMed Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CytoMed Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CytoMed Therapeutics‘s full profile, request access.

Request a free trial

CytoMed Therapeutics Investments (1)

CytoMed Therapeutics’s most recent deal was a Corporate Asset Purchase with TC BioPharm (Portfolio of Synergistic Assets). The deal was made on 18-Nov-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
TC BioPharm (Portfolio of Synergistic Assets) 18-Nov-2025 Corporate Asset Purchase Buildings and Property
To view CytoMed Therapeutics’s complete investments history, request access »

CytoMed Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view CytoMed Therapeutics’s complete esg history, request access »

CytoMed Therapeutics FAQs

  • When was CytoMed Therapeutics founded?

    CytoMed Therapeutics was founded in 2018.

  • Where is CytoMed Therapeutics headquartered?

    CytoMed Therapeutics is headquartered in Singapore, Singapore.

  • What is the size of CytoMed Therapeutics?

    CytoMed Therapeutics has 42 total employees.

  • What industry is CytoMed Therapeutics in?

    CytoMed Therapeutics’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is CytoMed Therapeutics a private or public company?

    CytoMed Therapeutics is a Public company.

  • What is CytoMed Therapeutics’s stock symbol?

    The ticker symbol for CytoMed Therapeutics is GDTC.

  • What is the current stock price of CytoMed Therapeutics?

    As of 16-Nov-2026 the stock price of CytoMed Therapeutics is $0.77.

  • What is the current market cap of CytoMed Therapeutics?

    The current market capitalization of CytoMed Therapeutics is $9.2M.

  • What is CytoMed Therapeutics’s current revenue?

    The trailing twelve month revenue for CytoMed Therapeutics is $254K.

  • Who are CytoMed Therapeutics’s competitors?

    Fate Therapeutics, Century Therapeutics, Autolus, Bristol-Myers Squibb, and Gilead are some of the 6 competitors of CytoMed Therapeutics.

  • What is CytoMed Therapeutics’s annual earnings per share (EPS)?

    CytoMed Therapeutics’s EPS for 12 months was -$0.23.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process